SCHEMBL23668409

SCHEMBL23668409

CC(C)c1cc(C#N)cc(C2CC2)c1CC(=O)NS(=N)(=O)c1ccc(CN(C)C)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NLRP3 Q96P20 5/20 0.44
LSS P48449 1/20 0.35
SMYD3 Q9H7B4 1/20 0.34
BDKRB1 P46663 1/20 0.32
TAS2R14 Q9NYV8 1/20 0.32
SOAT2 O75908 1/20 0.32
MYC P01106 1/20 0.32
SOAT1 P35610 1/20 0.32
MAP2K3 P46734 1/20 0.32
STAT3 P40763 1/20 0.31
ADAMTS4 O75173 1/20 0.30
MMP13 P45452 1/20 0.30
RORC P51449 1/20 0.30
TSHR P16473 1/20 0.30
ROCK2 O75116 1/20 0.30
PSEN1 P49768 1/20 0.30
PSEN2 P49810 1/20 0.30
APH1B Q8WW43 1/20 0.30
NCSTN Q92542 1/20 0.30
APH1A Q96BI3 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29687146 1.00 NLRP3 (0.44) NLRP3LSSSMYD3BDKRB1TAS2R14
SCHEMBL29687811 1.00 NLRP3 (0.44) NLRP3LSSSMYD3BDKRB1TAS2R14
SCHEMBL29687132 0.90 NLRP3 (0.52) NLRP3LSSTAS2R14SOAT2MYC
SCHEMBL23668370 0.90 NLRP3 (0.52) NLRP3LSSTAS2R14SOAT2MYC
SCHEMBL29687431 0.88 NLRP3 (0.41) NLRP3
SCHEMBL23668441 0.88 NLRP3 (0.41) NLRP3
SCHEMBL23668418 0.87 NLRP3 (0.49) NLRP3SMYD3BDKRB1
SCHEMBL29687556 0.87 NLRP3 (0.49) NLRP3SMYD3BDKRB1
SCHEMBL23668419 0.87 NLRP3 (0.47) NLRP3LSSSOAT2MYCSOAT1
SCHEMBL29687534 0.87 NLRP3 (0.47) NLRP3LSSSOAT2MYCSOAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230079631-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2023-03-16 US disclosed
US-11370763-B2 Compounds and compositions for treating conditions associated with NLRP activity NOVARTIS AG (CH) 2022-06-28 US disclosed
US-20210230129-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2021-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079631-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NLRP1, NLRP3, NOD1 NLRP3 2/4885LSS 1248/4885SMYD3 4658/4885
US-20210230129-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NLRP3, NLRP1, IAPP NLRP3 1/4885LSS 1119/4885SMYD3 4853/4885
US-11370763-B2 Compounds and compositions for treating conditions associated with NLRP activity NLRP3, NLRP1, IAPP NLRP3 1/4885LSS 1119/4885SMYD3 4853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.